A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...